Regencell Bioscience Holdings Limited (RGC)
NASDAQ: RGC · Real-Time Price · USD
5.72
+0.10 (1.78%)
At close: Jul 24, 2026, 4:00 PM EDT
5.79
+0.07 (1.22%)
After-hours: Jul 24, 2026, 7:59 PM EDT
RGC Market Cap
RGC has a market cap or net worth of $2.83 billion as of July 24, 2026. Its market cap has decreased by -61.25% in one year.
Market Cap
2.83B
Enterprise Value
2.83B
1-Year Change
-61.25%
Ranking
Category
Stock Price
$5.72
ChartMarket Cap Chart
Since the IPO on July 16, 2021, RGC's market cap has increased from $120.10M to $2.83B, an increase of 2,259.79%. That is a compound annual growth rate of 87.60%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 24, 2026 | 2.83B | -72.71% |
| Dec 31, 2025 | 10.38B | 16,053.85% |
| Dec 31, 2024 | 64.28M | -52.95% |
| Dec 29, 2023 | 136.63M | -62.35% |
| Dec 29, 2022 | 362.93M | -12.12% |
| Dec 31, 2021 | 413.00M | 243.88% |
| Jul 16, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Indivior Pharmaceuticals | 4.96B |
| Kiniksa Pharmaceuticals International, | 4.87B |
| Supernus Pharmaceuticals | 2.72B |
| BioCryst Pharmaceuticals | 2.42B |
| Prestige Consumer Healthcare | 2.32B |
| HUTCHMED (China) | 1.97B |
| Amylyx Pharmaceuticals | 1.94B |
| Bausch Health Companies | 1.68B |